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ABSTRACT 
 
 
Carbonic anhydrases (CAs) family are metalloenzymes, involved in pH 
control, catalysing the reversible conversion of carbon dioxide to protons 
and bicarbonate. Until now, 16 isoenzymes have been identified with 
different tissue distribution, subcellular localization and molecular 
biophysical properties.  
Among them, carbonic anhydrase IX (CA-IX) is a hypoxic marker 
because the master regulator of hypoxia, named Hypoxia Inducible Factor 
1 (HIF-1), promotes its expression. 
Thanks to its catalytic activity, CA-IX reduces extracellular pH. The acid 
microenvironment increases cancer cell proliferation and invasion, giving 
to CA-IX an important role during the cancer progression. 
Unlike other CAs, many studies have demonstrated that CA-IX is 
expressed only in few normal tissues, whereas it becomes overexpressed 
in many types of cancer. Therefore, the targeting of CA-IX, using specific 
tools, opens new important fields to improve the conventional therapies 
and the early diagnosis in cancer. 
Based on these evidences, we would generate new strategies able to target 
CA-IX. To this end, nucleic acid-based aptamers are emerging as new 
tools perfectly suitable to different fields. 
Aptamers are selected by an in vitro combinatorial chemistry approach, 
named Systematic Evolution of Ligands by Exponential enrichment 
(SELEX), and they are able to bind with high affinity and specificity 
virtually any given molecule. Compared to monoclonal antibodies, they 
have a small size that results in their rapid tumour penetration; they are 
not immunogenic and could be easily modified to increase their in vivo 
stability.  
Thus, in this study we describe the selection of RNA-based aptamers 
directed against the extracellular domain of CA-IX. 
Firstly, we performed two different cell-based SELEX protocols that 
allowed the enrichment for CA-IX specific aptamers.  
Furthermore, we characterized and improved the two best sequences 
selected, named S-47s1 and S-51s1, that we are still studying to handle a 
final product usable for diagnostic and therapeutic purposes. 
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1.  BACKGROUND 
 
1.1 Hallmarks of cancer 
 
Cancer is a class of diseases characterized by out-of-control cell growth 
[1].  
It is the second leading cause of death in the world after cardiovascular 
diseases. 
By the mid-1980s, since when researchers defined genomic alterations 
(nucleotide substitutions, chromosomal copy number alterations, and 
DNA rearrangements) [2] of two principal cancer-causing genes, named 
oncogenes and tumour suppressor genes , lot of new progresses have been 
made to better understand the molecular basis of the cancer. 
In 2000, Hanahan and Weinberg proposed six hallmarks of cancer to 
clarify how the normal cells can progressively evolve to a neoplastic 
phenotype. 
They postulated that cells become able to acquire a succession of 
hallmark capabilities (sustaining proliferative signalling, evading growth 
suppressors, activating invasion and metastasis, enabling replicative 
immortality, inducting angiogenesis, resisting to cell death), that improve 
their tumorigenesis and malignancy [3] 
In 2010, always Hanahan and Weinberg added other two emerging 
hallmarks [4]:  
 the capability to modify the cellular metabolism to support 
neoplastic proliferation. 
 the capability of cancer cells to evade immunological response, in 
particular by T and B lymphocytes, macrophages, and natural killer 
cells.  
In the last few years, as Caroline Wigerup shows (Fig.1), the eight 
hallmarks seems to be regulated by tumour hypoxia including cell 
proliferation, apoptosis, altered metabolism, immune responses, genomic 
instability, vascularization, invasion and metastasis [5].  
Thus, the linkage emerged between the hypoxic condition and cancer 
could represent a new prognostic/predictive markers to improve the 
conventional therapies and to improve the early diagnosis of the cancer. 
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Fig.1: Hypoxia and HIFs regulate hallmarks of cancer and multiple cancer 
phenotypes. The hypoxia regulates treatment resistance, vascularization, 
dedifferentiation, genomic instability, survival, immune response, invasion and 
metastasis. (From Wigerup C. et al. 2016)  
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1.5 Aptamers 
 
1.5.1 Composition and advantages of aptamers 
 
Aptamers are short synthetic single stranded nucleic acids able to bind 
tightly to a target molecule [55]. 
The “aptamer” means “to fit” (aptus) in latin, that reflects two their 
important characteristics (Fig. 8):  
 ability to fold into complex tertiary structures; 
 ability to bind with high affinity and specificity to their targets. 
 
 
 
 
Fig. 8  Aptamers: Schematic representation of the aptamer functionality. (From 
Stoltenburg R. et al. 2007) 
 
 
Aptamers act by directly binding to the protein target without interfering 
with its expression, unlike other small noncoding RNAs either natural or 
artificial, such as antisense, ribozymes, siRNAs and microRNAs 
(miRNA) that inhibit gene expression [56]. 
Aptamers are small nucleic acids of DNA or RNA, showing different 
characteristics. 
The DNA aptamers are more stable due to the lack of 2′-OH groups.  
However, there are numerous advantages of RNA aptamers. 
Firstly, RNA aptamers make more structure thanks to strong intra strand 
RNA–RNA interactions [57].  
Moreover, their stability can be enhanced using different types of 
modifications, such as the substitution of the 2’-ribose [58] with 2′-fluoro, 
2’-amino pyrimidine (2’-F-Py, 2’-NH2-Py) or 2′-O-alkyl.  
Modified RNA aptamers may survive, to degradation by nucleases, in 
vivo for several hours. 
Thus, the RNA aptamers represent an attractive alternative as diagnostics 
and therapeutic tools compared to their peptide and monoclonal antibody 
counterparts [59-62] such as (Fig. 9): 
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1. easy chemical synthesis that results in a little or no batch-to-batch 
variation; 
2. small size around 15-40kDa that allows a good penetration in 
tumour tissue; 
3. low or no immunogenicity;  
4. easy editing to improve their stability and half-life. 
Furthermore, the oligonucleotides composition of the aptamers gives 
them a great stability at high temperatures compared to monoclonal 
antibodies and peptides that have limited shelf life, undergoing to 
denaturation at high temperature.   
 
 
 
 
 
Fig. 9. : Advantages of aptamers. 
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1.5.2 Aptamer production: SELEX technology 
 
The SELEX technology was developed in 1990. It is an evolutionary in 
vitro combinatorial chemistry process used to identify aptamers as 
specific ligands of a given target from large pools of different 
oligonucleotides [63].  
The starting point for the generation of aptamers is the chemical synthesis 
of a single-stranded nucleic acid (RNA, DNA) library of large sequence 
complexity. A typical oligonucleotide library contains random sequences 
of 20–50 bases flanked by two constant regions that include primer sites 
for PCR amplification (Fig.10). Randomization is used to create possible 
sequences of enormous diversity (i.e. with n nucleotides in randomized 
region, 4n different molecules), which generates a vast array of different 
conformations with different binding properties. As schematized in figure 
10, the SELEX method includes several steps: (i) incubation of the library 
with the target molecule under favourable binding conditions; (ii) 
partitioning of molecules that, under the employed conditions, adopt 
conformations that permit binding to a specific target from other 
sequences; (iii) dissociation of the nucleic acid-protein complexes and 
(iv) amplification of the nucleic acids pool. The pool obtained from the 
first cycle will be then the starting pool for the next rounds of selection, 
thus reiterating these steps the library enriched in sequences that bind to 
the target is generated. After the final round, the resulting pool is 
subjected to DNA sequencing. Sequences corresponding to the initially 
variable region of the library are screened for conserved regions and 
structural elements indicative of potential binding sites and, subsequently, 
tested for their ability to bind specifically to the target molecule.  
SELEX technology usually requires different cycles of selection, around 
eight or more, in order to isolate aptamers with nanomolar affinity. 
Particularly, if the SELEX technology is performed on a protein, the 
rounds could be lesser than the SELEX technology performed on cells or 
tissues. 
Even if many aptamers are still selected by the traditional in vitro 
methodology, over the last few years considerable efforts have been 
focused on automating in vitro selection procedures [64], thereby 
accelerating aptamers discovery. 
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Fig. 10. Schematic representation of the SELEX technology. The RNA/DNA 
aptamers library contains a random sequence of 20–100 bases flanked by two constant 
regions. These constant regions include primer sites for PCR/RT-PCR amplification and 
transcription. The library is incubated with the target, not binding sequences are 
discarded whereas bound aptamers are recovered and amplified. (Adapted from Esposito 
C.L. et al 2011) 
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1.5.3 Cell-based SELEX 
 
A great promise in developing specific molecular probes for disease 
biomarkers is recently represented by the intact cell-based SELEX 
strategy, that allows to select nucleic acid aptamers against living cells 
[65]. 
Aptamer selection approach that targets the cell surface open a new path 
which presents two major advantages: i) direct selection without prior 
purification of membrane-bound targets, ii) access to membrane proteins 
in their native conformation similar to the in vivo conditions. By using 
living cells as targets, aptamers able to discriminate cells from distant 
tumour types like small lung cancer cells versus large cell lung cancer 
[66], T-cell acute lymphocytic leukemia (ALL) versus B-cell lymphoma 
[67] and colon cancer cells versus other cancer cells [68] have been 
generated. Furthermore, by the SELEX technology against whole-living 
cells in culture [69] it was demonstrated that even by using complex 
targets as intact cells, it is possible to obtain aptamers against rare 
antigens if specifically expressed on the target cell.   
In this regard, a panel of aptamers that bind a type of human malignant 
glioblastoma cells, discriminating them from non-tumorigenic 
glioblastoma cells, was isolated by a differential cell-SELEX approach 
[70]. In addition, the great advances in cell-SELEX offer also the 
opportunity to develop innovative approaches to identify and isolate 
cancer stem cells that are emerging as important target to develop more 
effective cancer therapy [71]. 
During the cell-SELEX strategy, to avoid the selection of ligands that 
recognize multiple surface proteins along with the target of interest, the 
counter- or negative-selection is critical. 
A negative selection step using negative cells was included to enhance the 
specificity of the aptamers and prevent the enrichment of aptamers for 
abundant non-specific proteins. 
Thus, for each cycle of the cell-SELEX strategy, the library is first 
incubated with non-target cells as counter-selection step (negative 
selection). Unbound aptamers are, then, recovered and incubated with the 
target cells. Bound aptamers are recovered and amplified (see Fig 11). 
Moreover, to improve the affinity and specificity of the aptamers the 
selective pressure during the cell-SELEX protocol is increased changing 
several conditions: 
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1. The increase of the washes number after the incubation is 
important to eliminate weakly bound or unbound aptamers.  
2. the reduction of the cells number is important to reduce the 
quantity of the target molecule in order to recover only the aptamers with 
the best affinity and discard the aptamers with the limited binding 
capability.  
3. the increase of the counter-selection numbers instead is important 
to discard the most of aptamers recognizing non-specific target 
molecules. 
4. the addition of polyanionic nucleic acid, as yeast tRNA, salmon 
spermidine or polyinosine, avoids binding depending only on the opposite 
charge between basic proteins and the negatively charged nucleic acids.  
The cell-SELEX approach has been further developed to discriminate 
even different properties in the same cancer cell type (such as 
malignancy, therapeutic response, metastatic potential).  
Moreover, to cell-SELEX, even a tumour implanted in mice (in vivo-
SELEX) have been used to select aptamers [72]. 
Recently, more sophisticated approaches combine fluorescence activated 
cell sorting (FACS) technology with in vitro selection (FACS–SELEX) 
has been performed [73], thus enabling a live-cell/dead-cell separation 
within a cultured cell mixture.  
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Fig. 11. Cell-based SELEX.  a) A pool of RNAs is incubated with non-target cells 
(counter-selection). Unbound sequences in the supernatant were recovered, and 
incubated with cells overexpressing the target for the selection step (positive selection). 
Unbound sequences were discarded by washings and bound sequences were recovered 
by total RNA extraction. b) Cell-based SELEX protocol to identify multiple ligands 
specifically. recognizing a cell phenotype, without prior knowledge of the target protein. 
(Catuogno S. et al. 2017) 
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1.6 Aptamers in therapy and diagnosis 
 
1.6.1 Modifications of aptamers for clinical applications 
 
Aptamers usable for clinical applications are usually modified in order to 
optimize their pharmacokinetic (PK) and pharmacodynamic (PD) profiles 
(see Fig. 12).  
Since aptamers, especially RNA-based aptamers, are rapidly degraded by 
nucleases in whole organisms, major efforts have been addressed to 
improve their stability by a variety of approaches [74].  
The most typical modifications to enhance the stability of aptamers are 
the substitution of the 2’-ribose [17]. RNA aptamers with 2′-fluoro, 2’-
amino pyrimidine (2’-F-Py, 2’-NH2-Py) or 2′-O-alkyl nucleotides 
modifications may survive for several hours in vivo against degradation 
by nucleases.  
Another example of modified nucleic acids is represented by the 
Spiegelmers. They do not contain additional groups added to the sugar 
moieties, but are enantiomers of natural nucleic acids [75]. In particular, 
the natural D-nucleic acids are substituted with enantiomeric L-nucleic 
acids. This property prevents recognition by nucleases, increasing the 
stability. 
A hurdle in administering of aptamers to patients for many therapeutic 
applications is a short circulating half-life due to their small size. While a 
low molecular weight can be an advantage because it allows economical 
chemical synthesis and better target accessibility, it promotes rapid 
clearance by the renal system. By simply increasing the molecular weight 
of the aptamers, the circulating half-life can be significantly extended.  
The most common method to increase the aptamers size is to add a 
polyethylene glycol (PEG) moiety or cholesterol tail [76].  
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Fig. 12. Aptamer modifications. Scheme of the most typical modifications used to 
improve aptamer nuclease resistance (red) or its pharmacokinetic profile (green).  
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1.6.2 Aptamers as therapeutics 
 
In the last years, the development of aptamers as therapeutics has 
primarily involved aptamers that bind and inhibit the activity of their 
protein targets. 
The list of aptamers against important therapeutic targets is growing 
rapidly and a handful of aptamers is now in clinical trials as therapeutic 
agents (see Table 1).  
To date, the most successful therapeutic application is represented by an 
RNA aptamer, named Macugen, binding and antagonizing the action of 
Vascular Endothelial Growth Factor (VEGF), a growth factor that 
promotes the blood vessel formation (vascularization) [77].  
Macugen (or Pegaptanib, marketed by Pfizer) has been demonstrated in 
phase III clinical trials to be effective for diabetic retinopathy treatment. 
The aptamer has been fully approved by the Food and Drug 
Administration (FDA) in December 2004 for the treatment of age-related 
macular degeneration (AMD). It is characterized by the formation of a 
neovascular membrane leaking blood and fluid under the retina with 
consequent destruction of the macula and loss of vision [78]. The aptamer 
binds and antagonizes the action of VEGF-165, the VEGF isoform 
preferentially involved in pathological ocular neovascularization. With 
the intent to improve the pharmacodynamic and pharmacokinetic 
properties of this 28-mer aptamer, it was chemically modified with 2′-F-
Py and 2′-OMe-Pu, capping, and linkage to a 40kDa branched PEG 
molecule, which increases the intravitreal residence time of the molecule.  
Different studies have been carried out to assess the clinical cost-
effectiveness of Macugen comparing to Ranibizumab (Lucentis, 
Genentech), a monoclonal antibody targeting all isoforms of human 
VEGF-A, approved in 2006 by the FDA for the treatment of exudative 
AMD.  
Both drugs show comparable therapeutic efficacy and mild adverse 
events, while the economic evaluation varies considerably depending on 
the methodology for cost-effectiveness used in different studies. 
Many other aptamers, not yet approved by the FDA, are currently in 
clinical trials.  
Among them, it is very interesting for cancer therapy the AS1411 DNA 
aptamer (AGRO100) directed against nucleolin [79], a protein often 
overexpressed on the surface of cancer cells. This DNA aptamer is part of 
the guanine-rich oligonucleotide class of aptamers that form G-quartets, a 
structural element that exhibits a proliferative activity. 
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Once bound to nucleolin, the AS1411 aptamer is taken into the cancer 
cell, where it causes cellular death by apoptosis through inhibition nuclear 
factor-κB (NF-κB) [80] and Bcl-2 [81] pathways.  
It showed its effectiveness as an anticancer therapy for different solid 
human malignancies as well as for acute myeloid leukemia (AML) and it 
is currently in phase IIb clinical trial to evaluate its effectiveness in 
combination with high-dose of cytarabine in patients with relapsed and 
refractory AML. 
 
 
 
 
 
Table 1. Aptamers in on-going or completed clinical trials. (From Zhenjian Z. et al. 
2017) 
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1.6.3 Aptamers as delivery agents 
 
The aptamers can be also internalized together with their target receptor. 
For this reason, they can be used to deliver any kind of secondary 
reagents to a given cancer cell or tissue (Fig. 13).  
 
 
 
Fig. 13. Aptamers as delivery agents. Aptamers that bind to cell surface receptors can 
be used to deliver small interfering RNAs (siRNAs and miRNAs), toxins, radioisotopes, 
and chemotherapeutic agents to target cells. (From Catuogno S. 2013) 
 
In this way, only targeted cells will be exposed to the secondary reagent, 
thus increasing the efficacy of a given therapy as well as attenuating the 
overall toxicity of the drug [82]. In this regard, currently an increasing 
number of aptamers targeting cancer cell surface epitopes have been 
successfully used for the specific delivery of active drug substances both 
in vitro and in vivo, including nanoparticles, anti-cancer therapeutics, 
small interfering RNAs (siRNAs), microRNAs, toxins [83], enzymes 
[84], radionuclides [85], viruses [86]. 
Several cell-internalizing aptamers against surface epitopes of cancer 
cells have been successfully used as targeting vehicles. These include 
aptamers against the protein tyrosine kinase 7 (PTK7), nucleolin, prostate 
specific membrane antigen (PSMA), mucin 1 (MUC1) and EGFRwhich 
have been selected through either protein- or cell-SELEX strategies [87]. 
 
22 
 
 
To date, the 2’F-Py-RNA aptamers A9 and A10 have been characterized 
for targeted delivery.. These aptamers, binding to extracellular domain of 
PSMA, have been used to deliver secondary molecule such as 
nanoparticles, quantum dots, toxin or siRNA to prostate cancer cells [88]. 
As shown in figure 14, A9 and A10 have been linked to siRNAs by 
covalent or non-covalent conjugation. Another promising delivery 
molecule is the phototoxic aptamer against MUC1, a membrane specific 
marker expressed on a broad range of epithelial cancer, that carries a 
cytotoxic cargo such as the light-activated PDT drug, chlorin e6, that 
produces cytotoxic singlet oxygen species. After light activation, the 
complex kills selectively MUC1 expressing cells [89]. In addition, John 
Rossi’s group used a RNA aptamer against gp120 for targeted delivery of 
siRNA against Human Immunodeficiency Virus (HIV) infections [90].  
Aptamer-siRNA provides new promising therapeutic options [91].  
Furthermore, recent papers also explored the use of aptamers to deliver 
microRNAs as cancer therapeutics. 
Recently, Esposito et al. demonstrated the in vivo effectiveness of an 
aptamer-miRNA conjugate for lung cancer targeting. The authors 
designed a dual-function molecules containing an RNA aptamer 
(GL21.T), directed against the RTK Axl, covalently linked to miRNA let-
7g [92]. The same aptamer was also used for the delivery of miR-212 to 
restore TRAIL-mediated cytotoxicity in NSCLC cells [93]. On the other 
end, Catuogno et al. described for the first time an aptamer-based system 
for the delivery of therapeutic single strand antimiRs [94]. Furthermore, 
very recently miRNA and antimiR delivery has been integrated 
developing a novel combined therapeutic approach for glioblastoma stem-
like cells (GSCs) therapeutic targeting [95].  
Moreover, the non-covalently link of the drugs to the aptamers was 
studied in order to understand if there is an abolishment of the aptamer 
binding and if the drug is released from the aptamer.  
This model was studied with doxorubicin (DOX) intercalated with the 
aptamers against PSMA for prostate cancer [96], MUC1 [97].  
This doxorubicin approach has shown toxicity levels compared to the free 
doxorubicin, but only in the cancer cells, reducing general toxicity or 
cardiotoxicity thanks to the specific aptamer delivery. 
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Fig. 14. A9-A10 conjugated with siRNA . (a) Using biotin, two aptamers and 
biotinylated siRNAs are non-covalently assembled via streptavidin; (b) Added at the end 
of aptamer complementary sequence to the antisense strand of the siRNA sequence, the 
chimera is formed by annealing of the aptamer to the siRNA antisense strand; (c) the 
aptamer portion of the chimera is truncated, and the sense and antisense strands of the 
siRNA portion are swapped. A two-nucleotide 3′-overhang and a PEG tail are added to 
the chimera; (d) the 3′-terminus of the aptamer is conjugated to the sense strand of the 
siRNA, followed by a 10-mer loop sequence and then by the antisense strand of the 
siRNA. (From Cerchia L. et al. 2011) 
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1.6.4 Aptamers in cancer imaging, diagnosis and biomarker 
discovery.  
 
In the early stage of tumorigenesis, the cancer cells number is very low 
and for this reason, the detection is an important challenge.  
Thus, to find new methods high sensitive to detect cancer cells are very 
important.  
Thanks to their characteristics, aptamers have also started to play 
increasingly important roles in diagnosis of human disease [98]. 
Indeed, aptamers can be functionalized using fluorophores, 
superparamagnetic iron oxide nanoparticles, Mn3O4- or gold 
nanoparticles, radioisotopes and biotin. These characteristics make the 
aptamers suitable as ligands for protein detection in a great number of 
different methodologies.  
Due to their small size (8-15kDa) in comparison to antibodies (150kDa), 
aptamers havea rapid tumour penetration and blood clearance. 
Hicke et al. were the first that published the use of a radiolabelled 
aptamer, named TTA1, for in vivo tumour target imaging [99]. 
TTA1 is a RNA modified aptamer against tenascin-C, an extracellular 
matrix protein upregulated in a number of tumours such as breast, lung, 
colon, prostate, glioblastoma, and lymphoma [100].  The aptamer was 
conjugated to the Technetium-99m (99mTc) and it was intravenously 
injected in xerographs mice bearing glioblastoma (U251) and breast 
(MDA-MB-435) [99].The authors, using single photon emission-
computed tomography (SPECT), obtained a good tissue penetration and 
an important ratio tumour-to-blood of TTA1 aptamer. 
This study suggests a quickly blood clearance and long tumour retention.  
As shown in table 2, many other DNA or RNA aptamers have been 
developed for diagnosis of human diseases. 
Moreover, aptamers are useful in many imaging techniques such as 
fluorescence and bioluminescence imaging, magnetic resonance imaging 
(MRI), positron emission tomography (PET), single photon emission 
tomography (SPECT), computed tomography (CT) and ultrasound (US) 
[101,102]. 
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Table 2. Recently developed aptamers for the diagnosis of human diseases. (From 
Zhuo Z. et al. 2017) 
 
Until now, the aptamers are used for in vitro purpose such as dot-blot 
[103], western blot applications [104, 105], in the sandwich assay called 
ELONA (Enzyme Linked Oligonucleotide Assay). 
In addition to their role as imaging tools, aptamers can also aid in clinical 
in vitro diagnosis of diseases and discovery of new biomarkers. 
Recently, several groups developed aptamer-based biomarker discovery 
platforms.  
For example, Gold co-workers described an aptamer chip for the 
biomarker discovery. The system is able to measure thousands of proteins 
together from serum or plasma samples [106].  
Novel aptamer-based technologies will continue to evolve and they could 
provide enormous opportunities in different diagnostic area. 
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3. MATERIALS AND METHODS 
 
3.1 Cell culture 
 
Cell lines were purchased from the ATCC (LG Standards, Milan, Italy). 
COS7, MDA-MB-231 and U87MG cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and 100 U/ml 
penicillin/streptomycin. All cell culture reagents were purchased from 
Sigma (St Louis, MO). 
 
3.2 Hypoxia induction  
 
Physical method: 2x105 U87MG cells were seeded in p35 cell plate in 
serum-free medium, and put in the hypoxic incubation chamber 
maintained at 5% O2. The cells were recovered at different times (6, 24, 
48h). 
Chemical methods: 2x105 U87MG or MDA-MB-231 cells were seeded in 
p35 cell plate. U87MG or MDA-MB-231 cells were incubated with 100-
150-200μM of Cobalt (II) Chloride hexahydrate (Sigma, St Louis, MO) 
dissolved in the serum-free medium and put in a conventional incubator 
(37°C; 5% C02). At different times (1, 6, 24h) the cells were recovered. 
 
3.3 CA-IX cDNA transfection and acidic condition 
 
Human CA-IX ORF clone (NM_001216) (Origene, Rockville, USA) was 
transfected with Lipofectamine 2000 (Invitrogen, Waltham, MA, USA), 
according to the manufacturer’s protocol. 
For the acid condition, the MES buffer (morpholinoethanesulfonic acid) 
(Sigma, St Louis, MO) was added to the serum-free DMEM from 45 to 
90mM for different incubation times (30, 90, 180 minutes). The pH 
medium was measured by a pHmeter (Mettler Toledo, Columbus, 
Ohio,USA). 
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3.4 Immunoblotting 
 
Cells were washed twice in ice-cold phosphate-buffered saline (PBS) 
(Sigma St Louis, MO), and lysed in the JS buffer  containing: 
• 50 mM Tris-HCl pH 7.5  
• 150 mM NaCl 
• 1% Nonidet P-40 
• 2 mg/ml aprotinin 
• 1 mg/ml pepstatin 
• 2 mg/ml leupeptin 
• 10 mM Na3VO4 
Protein concentration was determined by Bradford assay (Biorad, 
Hercules, CA, USA). 
The cell lysates were denatured in Laemmli buffer (2% SDS , 5% β-
mercaptoethanol, 0,001% Bromophenol Blue, 10 % glycerol) for 5 
minutes at 100°C, and then subjected to SDS-PAGE.  
12% Acrylamide/bis-acrylamide gels were electroblotted into 
polyvinylidene difluoride (PVDF) membranes (Millipore Co., Bedford, 
MA, USA)  
Filters were probed with primary antibodies as indicated.  
The primary antibodies used are: anti-CA-IX (R&D Systems, 
Minneapolis, MN. USA); anti-HIF-1α (BD Biosciences, Qume Drive San 
Jose, USA); anti-α-tubulin (Santa Cruz Biotechnology, CA, USA); anti-
vinculin (Cell Signaling Technology, Danvers, MA); anti-β-actin (Santa 
Cruz Biotechnology, CA, USA). Donkey anti-goat, goat anti-mouse and 
goat anti-rabbit (Santa Cruz Biotechnology, CA, USA) were used as 
secondary antibodies. 
 
3.5 Immunofluorescence 
 
To assess CA-IX expression on the cell surface, MDA-MB-231 cells in 
normoxic condition or stimulated with CoCl2 (150μM) for 24h to mimic 
hypoxic condition, were seeded on poly-l-Lysine coated glass coverslips 
and incubated with anti-CA-IX antibody for 30 min at 37 °C prior to 
fixation. Cells were, then, fixed with paraformaldehyde 4% in PBS for 10 
minutes and incubated at 37°C for 30 minutes with Alexa568 secondary 
antibody (Invitrogen, Waltham, MA, USA). Coverslips were then 
mounted on microscope slides with Prolong Gold Antifade Reagent with 
DAPI (Invitrogen, Waltham, MA, USA) and visualized by confocal 
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microscopy. Images were obtained using a Zeiss 510 LSM confocal 
microscope with a 40 × oil objective. 
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3.6 Physiological cell-SELEX 
 
The SELEX cycle was performed essentially as described (Fitzwater and 
Polisky 1996). Transcription was performed in the presence of 1mM 2’-F 
pyrimidines and mutant T7 RNA polymerase (2.5u/ml T7 R&DNA 
polymerase, Epicentre Biotechnologies, Madison, Wisconsin) to improve 
yields.  
2’F-Py RNAs were used to increase the resistance of the aptamers to 
degradation by sieric nucleases. 2’F-Py RNAs were heated at 85°C for 5 
min, snap-cooled on ice for 2 min, and allowed to warm up to 37°C.  
The Hypoxic cell-SELEX protocol is composed by twelve cycles.  
Counter-selection step against normoxic MDA-MB-231 cells.  
To avoid the selection of aptamers recognizing normoxic targets  on 
MDA-MB-231 surface, the pool was firstly incubated on normoxic 
MDA-MB-231 for 30 min (up to round 6) or for 15 min (for the following 
rounds) at 37°C. 
In each cycle the SELEX conditions were changed such as the dimension 
of the cell culture dishes (150mm, 100mm, 50mm, 35mm). Unbound 
sequences were recovered for the selection step. 
 
Selection step against hypoxic MDA-MB-231cells.  
The recovered sequences were incubated on CoCl2-stimulated MDA-MB-
231 cells (to mimic the hypoxic condition).  
After several washings, sequences were recovered by total RNA 
extraction. 
During the selection process, the selective pressure was changed 
increasing washings number (from one for the first cycle up to five for the 
last cycles), decreasing the incubation time (from 30 to 15 min from 
round 7) and the dimension of the cell culture dishes (150mm, 100mm, 
50mm, 35mm). It was also increased the number of counter-selection 
steps from one to two from round 8. 
Moreover, the use of a non-specific competitor, named yeast tRNA 
(Sigma, St Louis, MO), was introduced at different concentrations: 
100μg/ml for the round 10 and 200μg/ml for the round 11; in the last two 
cycles (11 and 12) the pre-treatment with yeast tRNA before of the 2’F-
Py RNAs pool incubation was made. 
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3.7 Specific cell-SELEX 
 
The starting pool is represented by the 9th cycle of Physiological cell-
SELEX. 
The counter-selection step was performed against COS7 wild type 
(COS7-WT) cells to avoid the selection of aptamers that recognize 
proteins normally expressed on COS7 cells.  
The selection step was performed against transient transfected COS7 with 
the CA-IX cDNA (called COS7-CAIX) in order to select specific 
aptamers for the target. 
For each cycle, the pool of 2’F-Py RNAs was firstly incubated on the 
COS7 wild type cells at 37°C, the 2’F-Py RNAs that not bind these cells 
are recovered and incubated on CA-IX-COS7 for the selection step. 
After several washes, the sequences were recovered by total RNA 
extraction. 
During the SELEX process, the selective pressure was progressively 
enhanced increasing washings number (from five for the round 10a up to 
six for the rounds 11a and 12a), increasing the number of counter-
selection steps from two in 10a and 11a cycles to three for the last cycle 
(12a). The yeast tRNA 100μg/ml as a nonspecific competitor (Sigma, St 
Louis, MO) was used in 10a and 11a cycles; in the last two cycles 
(11aand 12a) it was also added the pre-treatment with yeast tRNA. 
Each cycle was checked for CA-IX expression. 
 
3.8 RT-PCR, mutagenic and non-mutagenic PCR for cell-SELEX 
method  
 
The RNA extracted from each SELEX cycle was retro-transcribed using 
Tetro Reverse Transcriptase Enzyme (Bioline, London, UK) according to 
the manufacturer’s protocol. The retro-transcription reaction was as 
follow: 90°C for 3min, 42°C for 15min and 50°C for 30min.  
The product was used for mutagenic PCR, characterized by higher 
concentration of MgCl2 (6mM) and dNTP 1mM, using 0.5U/μl of 
FIREpol DNA Polymerase (Microtech, Milan, Italy) and 0,3μM primers: 
N40 (Forward):5’-TTCAGGTAATACGACTCACTATAGGGAAGAGA 
AGGACATATGAT-3’ 
N40 (Reverse): 5’-TCAAGTGGTCATGTACTAGTCAA -3’ 
The reaction was as follow: 95°C for 5min, 10 cycles of 95°C for 1 min, 
65°C for 1min and 72°C for 1 min, and a final extension of 72°C for 
1min. 
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The last SELEX cycle is amplified by non-mutagenic PCR using 0.1U/μl 
of FIREpol DNA Polymerase and 200μM dNTP, not adding MgCl2 to 
that contained in the Taq Buffer.  
The reaction was as follow: 95°C for 5min, 8 cycles of 95°C for 30 sec, 
65°C for 1min and 72°C for 1 min, and a final extension of 72°C for 
5min. 
Amplified DNA was purified using Amicon Ultra Centrifugal Filters 
(Millipore, Massachusetts, USA). 
At the end of SELEX method, sequences of the pools were subjected to 
cloning with TOPO-TA cloning kit (Invitrogen, Waltham, MA, USA).  
The sequences have been analysed for multiple alignment (ClustalW by 
EMBL-EBI) and structural elements (MFOLD by unafold) indicative of 
potential binding sites. 
 
3.9 Cell binding assay by RT-qPCR 
 
The binding assay of individual aptamers was performed in 6-well plates 
in triplicate on COS7-CA-IX cells as positive cells and COS7-WT as 
negative cells. 105 cells per well were seeded and, 24 hours after 
transfection, were incubated for 30 minutes with serum-free medium in 
presence of yeast tRNA 200μg/μl and MES buffer (60mM). Then, 100nM 
of aptamers  were added for 15 min at 37°C. Following three washes with 
PBS to remove unbound aptamers, the bound sequences were recovered 
by TRIzol (Life Technologies, Carlsbad, CA, USA) containing 
0.5pmol/ml of reference control. The amount of bound RNAs was 
determined by RT-qPCR.  
At each experiment, cells cultured were counted. The obtained data were 
normalized to the reference control and to cell number.  
 
3.10 In vitro human serum stability 
 
2’-F-RNA S-47s1 and S-51s1 aptamers were incubated at 4μmol/l 
concentration in 87% human serum (Type AB Human Serum provided by 
Euroclone, Milan, Italy) from 1 to 72 hours at 37°C. 
At each time point 2μl (8 pmoles RNA) were recovered and treated with 
2,5μl of proteinase K solution (600 mAU/ml) for 1 hour at 37°C in order 
to remove serum proteins that interfere with electrophoretic migration. 
Following the addition of 9 μl  of denaturing gel loading buffer (1× TBE, 
95% formamide, EDTA 10mM and bromophenol blue), samples were 
stored at −80°C. All serum-RNA samples were analyzed on 15% 
32 
 
polyacrylamide/urea 7M denaturing gel. The gel was stained with 
ethidium bromide and visualized by UV exposure. 
 
 
3.11 ELONA (Enzyme-linked oligonucleotide assay) assay for human 
serum albumin 
 
Human serum albumin: C96 maxisorp nunc-immunoplate (Thermo Fisher 
Scientific, Waltham, MA, USA) were left untreated or coated with 25nM 
of human serum albumin (HAS) (Sigma, St Louis, MO) in 
Coating/Washing buffer (20 mM Tris HCl pH 7.4; 150 mM NaCl; 1 mM 
MnCl2; 0.5 mM MgCl2; 2 mM CaCl2) overnight at 4°C. 
Wells were washed once with Coating/Washing buffer and blocked for 2 
hours at room temperature (RT), with Coating/Washing buffer containing 
5% non-fat dried milk. Following two washes with Coating/Washing 
buffer, the biotinylated 2’-F-RNA S-47s1 and S51s1 aptamers were 
heated at 95 °C for 5’, snap-cooled on ice for 3min and allowed to warm 
up to 37°C for 10’ and, then, incubated for 2 hours at room temperature at 
different concentrations (10-100-1000nM) in Coating/Washing buffer 
containing 1,6% non-fat milk. After three washes with Coating/Washing 
buffer,  samples were incubated for 1 hour at room temperature with 
horseradish peroxidase (HRP)-conjugated Streptavidin (Thermo Fisher 
Scientific, Waltham, MA, USA) diluted 1:1000 in PBS. 
Following four washes with PBS, signals were reveled with 3,3',5,5'-
tetrametilbenzidina (TMB) substrate solution (Thermo Fisher Scientific, 
Waltham, MA, USA) and stopped with stop solution (H2SO4 0.16M) for 
TMB substrate (Thermo Fisher Scientific, Waltham, MA, USA). 
Absorbance at 450nm was measured with Multiskan FC Microplate 
Photometer (Thermo Fischer Scientific, Waltham, MA, USA). 
As positive control, wells were incubated with an anti-HSA biotinylated 
polyclonal antibody (concentration: 1:1000, Abcam; Cambridge, MA). 
The assay was performed in duplicate.  
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3.12 Flow cytometry analysis  
 
CA-IX expression in COS7 transfected with human CA-IX plasmid was 
detected by anti-human CA-IX primary antibody (R&D Systems, Milan, 
Italy). Alexa Fluor 488 donkey anti-goat IgG (Invitrogen, Milan, Italy) 
was used as secondary antibody. Cells were analyzed with FACS BD 
Accuri C6 (BD Biosciences, Franklin Lakes, New Jersey, USA). IgG 
antibody (Millipore, Burlington, MA, USA) was used as negative control. 
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4. RESULTS 
 
5. DISCUSSION 
 
6. CONCLUSIONS 
 
In conclusion, this study has identified new possible tools that are able to 
discriminate between CA-IX positive cells and CA-IX negative cells.  
Considering that the hypoxia phenotype and CA-IX expressing cells are 
involved in chemotherapy resistance and poor prognosis, the aptamers 
identified in this study could have an important role in detecting only the 
hypoxic cells and acid microenvironment. 
The study provide a new Selection strategy to successfully isolate 
aptamers with a very high specificity under physiological condition for in 
vivo applicability.  
Although more studies are needed to better understand the usefulness of 
the selected molecules, taken together, our findings represent an initial 
development of novel aptamer-based tools fo 
r CA-IX detection.  
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